A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
NCT ID: NCT00088621
Last Updated: 2014-04-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
61 participants
INTERVENTIONAL
2004-07-31
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial of Lurasidone in Treatment of Schizophrenia
NCT02002832
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
NCT01566162
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
NCT01143077
A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
NCT03627195
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
NCT05011669
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lurasidone 80 mg tablet
Lurasidone 80mg oral tablet taken once a day
Lurasidone 80mg tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lurasidone 80mg tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Successfully completed
* OR
* Patients must have been discontinued after a minimum of 2 weeks of treatment due to lack of efficacy
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sumitomo Pharma America, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director, MD
Role: STUDY_DIRECTOR
Sumitomo Pharma America, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham Psychiatry Pharmaceutical
Birmingham, Alabama, United States
Summit Research Group
Little Rock, Arkansas, United States
Comprehensive NeuroScience
Cerritos, California, United States
Collaborative Neuro Science Network, Inc.
Garden Grove, California, United States
Optimum Health Services
La Mesa, California, United States
California Clinical Trials
San Diego, California, United States
CA Neutopsychopharmacology Clinical Research Institute (CNRI)
San Diego, California, United States
Pacific Clinical Research
Upland, California, United States
Comprehensive NeuroScience, Inc
Washington D.C., District of Columbia, United States
Segal Institute for Clinical Research
Fort Lauderdale, Florida, United States
Segal Institute for Clinical Research
North Miami, Florida, United States
University of South Florida, Department of Psychiatry and Behavioral Medicine
Tampa, Florida, United States
Comprehensive Neuroscience, Inc.
Hoffman Estates, Illinois, United States
Las Vegas, Nevada, United States
CNS Research Institute
Clementon, New Jersey, United States
Quantum Clinical Services Group
Philadelphia, Pennsylvania, United States
Community Clinical Research
Austin, Texas, United States
Future Search Trials
Austin, Texas, United States
Claghorn Lesem Research Clinic, Inc.
Bellaire, Texas, United States
InSite Clinical Research
DeSoto, Texas, United States
CBH Health, L.L.C - Dominion Hospital
Falls Church, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1050199
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.